Maricer P. Escalón, PhD

Eli Lilly and Company

Poster(s):

• 1512 - Pirtobrutinib after a Covalent BTK Inhibitor in Pretreated Chronic Lymphocytic Leukemia: A Phase 2 Dose Optimization Trial in Progress